Described herein are heteroaryl compounds as kinase inhibitors. Methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases are also described. Described herein are inhibitors of Brutons tyrosine kinase (Btk). Also described herein are irreversible inhibitors of Btk. Also described herein are reversible inhibitors of Btk. Further described are irreversible inhibitors ofBtk that form a covalent bond with a cysteine residue on Btk. Further described herein are irreversible inhibitors of other tyrosine kinases, wherein the other tyrosine kinases share homology with Btk by having a cysteine residue (including a Cys 481 residue) that can form a covalent bond with the irreversible inhibitor (such tyrosine kinases, are referred herein as "Btk tyrosine kinase cysteine homologs").Linvention concerne des composés hétéroaryle en tant quinhibiteurs de kinase. Des méthodes de synthèse de tels inhibiteurs et des méthodes dutilisation de ces inhibiteurs dans le traitement de maladies sont également décrits.
